Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2023-03-06

Last Posted Date: 2024-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 390

Registration Number: NCT05755360

Locations: 🇮🇹
A.O.U. Policlinico S.Orsola, Bologna, Italy
🇮🇹
A.O.U. Maggiore della Carità, Piemonte, Italy
🇮🇹
P.O. Praia a Mare, Praia a Mare, Italy

and more 22 locations

A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists

Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)

Interventions: Other: No treatment given

First Posted Date: 2023-03-06

Last Posted Date: 2023-06-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 602

Registration Number: NCT05755373

Locations: 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: NNC0194-0499
Drug: NC0194-0499

First Posted Date: 2023-02-24

Last Posted Date: 2024-06-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT05742919

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China

Persons With Obesity (PwO) Exploratory Research

Completed

Conditions: Obesity

Interventions: Other: No treatment given

First Posted Date: 2023-02-21

Last Posted Date: 2023-05-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT05736120

Locations: 🇮🇳
Novo Nordisk Investigational Site, Bengaluru, India

Attitudes and Unmet Needs Among Type 2 Diabetes Patients

Completed

Conditions: Type 2 Diabetes

Interventions: Other: No treatment given

First Posted Date: 2023-02-21

Last Posted Date: 2023-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 700

Registration Number: NCT05737810

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: NNC0194-0499

First Posted Date: 2023-02-14

Last Posted Date: 2023-12-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT05727644

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9

Phase 3

Recruiting

Conditions: SGA
ISS
Noonan Syndrome
Turner Syndrome

Interventions: Drug: Somapacitan

First Posted Date: 2023-02-13

Last Posted Date: 2024-06-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT05723835

Locations: 🇺🇸
Rocky Mt Ped and Endo, Centennial, Colorado, United States
🇵🇱
SPSK nr 1 im. prof.S.Szyszko w Zabrzu, Zabrze, Poland
🇺🇸
Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States

and more 13 locations

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2023-02-13

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 210

Registration Number: NCT05726227

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇩🇪
Auf der Bult - Klinik für Diabetologie, Endokrinologie, Gastroenterologie und Klinische Forschung, Hannover, Germany
🇩🇪
Universitätsklinikum Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin, Leipzig, Germany

and more 42 locations

A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Ziltivekimab B
Drug: Ziltivekimab D
Drug: Ziltivekimab C

First Posted Date: 2023-02-10

Last Posted Date: 2024-02-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 267

Registration Number: NCT05721989

Locations: 🇳🇱
ICON - location Groningen, Groningen, Netherlands
🇭🇺
ICON Budapest Phase I Unit, Budapest, Hungary

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Conditions: Adult Growth Hormone Deficiency

Interventions: Drug: Somapacitan

First Posted Date: 2023-02-08

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 400

Registration Number: NCT05718570

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
Keck Medical Center of USC - Outpatient Clinic, Los Angeles, California, United States

and more 30 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy